Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
Status:
Completed
Trial end date:
2012-08-02
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, single-blinded (investigator's blinded), active-controlled
(clindamycin [CLDM] 1% gel), parallel-group study in Japanese subjects with acne vulgaris to
demonstrate the efficacy of GSK2585823 (CLDM 1%-benzoyl peroxide [BPO] 3% gel) when applied
once or twice daily for 12 weeks. This study will also evaluate the safety of GSK2585823 when
applied topically either once or twice daily for 12 weeks.